Boosted Bacille Calmette-Guérin vaccine strategy significantly reduces tuberculosis relapse, scientists find

Tuberculosis (TB) remains 1 of the world's starring causes of death, and preventing post-treatment relapse continues to beryllium a large planetary wellness challenge. But a caller survey led by scientists astatine the Hackensack Meridian Center for Discovery and Innovation (CDI) reveals that combining an immunotherapy with the accepted Bacille Calmette-Guérin (BCG) vaccine drastically lowers the hazard of TB relapse successful preclinical models.